<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29582164</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-8798</ISSN><JournalIssue CitedMedium="Internet"><Volume>163</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Archives of virology</Title><ISOAbbreviation>Arch Virol</ISOAbbreviation></Journal><ArticleTitle>Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.</ArticleTitle><Pagination><StartPage>1851</StartPage><EndPage>1861</EndPage><MedlinePgn>1851-1861</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00705-018-3797-7</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is the most frequently detected causative agent in hand, foot, and mouth disease (HFMD) and is a serious threat to public health in the Asia-Pacific region. Many EV71&#xa0;vaccines are under development worldwide, and although both inactivated virus vaccines and virus-like particles (VLPs) are considered to be effective, the main focus has been on inactivated&#xa0;EV71vaccines. There have been very few studies on EV71 VLPs. In this study, using a strategy based on HIV gag VLPs, we constructed a gag-VP1 fusion gene to generate a recombinant baculovirus expressing the EV71 structural protein VP1 together with gag, which was then used to infect TN5 cells to form VLPs. The VLPs were characterized using transmission electron microscopy, electrophoresis and staining with Coomassie blue, and Western blotting. Mice immunized with gag-VP1 VLPs showed strong humoral and cellular immune responses. Finally, immunization of female mice with gag-VP1 VLPs provided effective protection of their newborn offspring against challenge with a lethal dose EV71. These results demonstrate a successful approach for producing EV71 VP1 VLPs based on the ability of HIV gag to self-assemble, thus providing a good foundation for producing high-titered anti-EV71 antibody by immunization with VLP-based gag EV71 VP1 protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China. drdongke@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhaowei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huizhong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xinsi Road No 569, 710038, Xi'an, Shaanxi, China. td_zhz@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2016KTZDSF01-07</GrantID><Agency>Science Technology Innovation Project in Shaanxi .</Agency><Country/></Grant><Grant><GrantID>81572974</GrantID><Agency>China Natural Sciences Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Arch Virol</MedlineTA><NlmUniqueID>7506870</NlmUniqueID><ISSNLinking>0304-8608</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054301">gag Gene Products, Human Immunodeficiency Virus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054301" MajorTopicYN="N">gag Gene Products, Human Immunodeficiency Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>CONFLICT OF INTEREST: All authors declare that they have no conflict of interest. ETHICAL APPROVAL: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. CONSENT FOR PUBLICATION: All authors consent to publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29582164</ArticleId><ArticleId IdType="pmc">PMC5999152</ArticleId><ArticleId IdType="doi">10.1007/s00705-018-3797-7</ArticleId><ArticleId IdType="pii">10.1007/s00705-018-3797-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30:3295&#x2013;3303. doi: 10.1016/j.vaccine.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SS, Yip CC, Lau SK, et al. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect. 2010;138:1071&#x2013;1089. doi: 10.1017/S0950268809991555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268809991555</ArticleId><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J Pediatr. 2016;59:395&#x2013;401. doi: 10.3345/kjp.2016.59.10.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2016.59.10.395</ArticleId><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 2008;7:868&#x2013;869. doi: 10.1016/S1474-4422(08)70207-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70207-2</ArticleId><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, et al. Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol. 2009;47:3653&#x2013;3662. doi: 10.1128/JCM.00630-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00630-09</ArticleId><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S, Sam IC, Yusof J, et al. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis. 2009;15:79&#x2013;82. doi: 10.3201/eid1501.080264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1501.080264</ArticleId><ArticleId IdType="pmc">PMC2660687</ArticleId><ArticleId IdType="pubmed">19116058</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wu S, Xiong Y, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One. 2014;9:e96051. doi: 10.1371/journal.pone.0096051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096051</ArticleId><ArticleId IdType="pmc">PMC4002479</ArticleId><ArticleId IdType="pubmed">24776922</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, et al. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011;37:313&#x2013;327. doi: 10.3109/1040841X.2011.580723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Cong H, Song L, et al. The nuclear protein Sam68 is redistributed to the cytoplasm and is involved in PI3K/Akt activation during EV71 infection. Virus Res. 2014;180:1&#x2013;11. doi: 10.1016/j.virusres.2013.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2013.11.020</ArticleId><ArticleId IdType="pubmed">24316008</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol. 2005;11:424&#x2013;433. doi: 10.1080/13550280591002531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280591002531</ArticleId><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li F, Pan Z, et al. Activation of PI3K/Akt pathway limits JNK-mediated apoptosis during EV71 infection. Virus Res. 2014;192:74&#x2013;84. doi: 10.1016/j.virusres.2014.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.07.026</ArticleId><ArticleId IdType="pubmed">25116390</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Fang X, Li J, et al. Enhancing immune responses of EV71 VP1 DNA vaccine by co-inoculating plasmid IL-12 or GM-CSF expressing vector in mice. Cell Mol Biol (Noisy-le-grand) 2016;62:35&#x2013;41. doi: 10.14715/cmb/2016.62.13.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.14715/cmb/2016.62.13.7</ArticleId><ArticleId IdType="pubmed">27188732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YI, Song JH, Kwon BE, et al. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Vaccine. 2015;33:6604&#x2013;6610. doi: 10.1016/j.vaccine.2015.10.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.103</ArticleId><ArticleId IdType="pubmed">26529069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushko P, Tretyakova I, Hidajat R, et al. Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology. 2017;501:176&#x2013;182. doi: 10.1016/j.virol.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.12.001</ArticleId><ArticleId IdType="pmc">PMC5266608</ArticleId><ArticleId IdType="pubmed">27936463</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallas HB, Zak A, Khera E, et al. Engineering virus-like particles for antigen and drug delivery. Curr Protein Pept Sci. 2016;19:112&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">27875963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdanowicz M, Chroboczek J. Virus-like particles as drug delivery vectors. Acta Biochim Pol. 2016;63:469&#x2013;473. doi: 10.18388/abp.2016_1275.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2016_1275</ArticleId><ArticleId IdType="pubmed">27474402</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Fang Y, Zhou P, et al. Chimeric virus-like particles elicit protective immunity against serotype O foot-and-mouth disease virus in guinea pigs. Appl Microbiol Biotechnol. 2017;101:4905&#x2013;4914. doi: 10.1007/s00253-017-8246-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-017-8246-0</ArticleId><ArticleId IdType="pubmed">28365796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H, Seong BL. Exploiting virus-like particles as innovative vaccines against emerging viral infections. J Microbiol. 2017;55:220&#x2013;230. doi: 10.1007/s12275-017-7058-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-017-7058-3</ArticleId><ArticleId IdType="pmc">PMC7090582</ArticleId><ArticleId IdType="pubmed">28243941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan T, Berman Z, Luo Y, et al. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. Sci Rep. 2017;7:40226. doi: 10.1038/srep40226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep40226</ArticleId><ArticleId IdType="pmc">PMC5220311</ArticleId><ArticleId IdType="pubmed">28067290</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert MA, Lytvyn V, Deforet F, et al. Virus-like particles derived from HIV-1 for delivery of nuclear proteins: improvement of production and activity by protein engineering. Mol Biotechnol. 2017;59:9&#x2013;23. doi: 10.1007/s12033-016-9987-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-016-9987-1</ArticleId><ArticleId IdType="pubmed">27830536</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, He Y, Lu J. Virus-like particles produced in pichia pastoris induce protective immune responses against coxsackievirus A16 in mice. Med Sci Monit. 2016;22:3370&#x2013;3382. doi: 10.12659/MSM.900380.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.900380</ArticleId><ArticleId IdType="pmc">PMC5036384</ArticleId><ArticleId IdType="pubmed">27659054</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Wu L, Chen L, et al. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine. 2016;34:4196&#x2013;4204. doi: 10.1016/j.vaccine.2016.06.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.06.058</ArticleId><ArticleId IdType="pubmed">27373596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xiao X, Zhao M, et al. EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge. BMC Res Notes. 2016;9:42. doi: 10.1186/s13104-015-1780-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-015-1780-x</ArticleId><ArticleId IdType="pmc">PMC4724958</ArticleId><ArticleId IdType="pubmed">26809443</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshaikhahmed K, Roy P. Generation of virus-like particles for emerging epizootic haemorrhagic disease virus: Towards the development of safe vaccine candidates. Vaccine. 2016;34:1103&#x2013;1108. doi: 10.1016/j.vaccine.2015.12.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.12.069</ArticleId><ArticleId IdType="pubmed">26805595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol. 2006;12:921&#x2013;927. doi: 10.3748/wjg.v12.i6.921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, Ye X, Li D, Jin X, Huang Z. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335&#x2013;2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007;18:537&#x2013;545. doi: 10.1016/j.copbio.2007.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2007.10.013</ArticleId><ArticleId IdType="pmc">PMC7126091</ArticleId><ArticleId IdType="pubmed">18083549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell NM, Lever AM. HIV gag polyprotein: processing and early viral particle assembly. Trends Microbiol. 2013;2(3):136&#x2013;144. doi: 10.1016/j.tim.2012.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2012.11.006</ArticleId><ArticleId IdType="pubmed">23266279</ArticleId></ArticleIdList></Reference><Reference><Citation>Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005;42:259&#x2013;277. doi: 10.1016/j.molimm.2004.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2004.06.028</ArticleId><ArticleId IdType="pubmed">15488613</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel RA, Errington J. Control of cell morphogenesis in bacteria: two distinct ways to make a rod-shaped cell. Cell. 2003;113:767&#x2013;776. doi: 10.1016/S0092-8674(03)00421-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00421-5</ArticleId><ArticleId IdType="pubmed">12809607</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335&#x2013;2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466&#x2013;471. doi: 10.1203/01.pdr.0000238247.86041.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>